Parameter
| Biomarker | STING | Full name | Stimulator of interferon genes | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnostic and therapeutic targets | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Diagnostic biopsy specimens (immunohistochemistry), cell lines (Western blot analysis, immunohistochemistry) | ||
| Pathobiological Mechanisms | STING transcription is activated in tumor T/NK cells, while it is downregulated in B-cell NHL. | ||||
| Clinical Availability Status | Research validation: Its specific expression in T/NK cell NHL has been confirmed, and the related cGAS-STING modulators have entered clinical trials, demonstrating potential for immunotherapy applications. | ||||
| Notes and Dynamics | The positivity rates of T/NK cell subtypes in NHL vary (7.7%-95%) and are independent of the patients' clinical-pathological parameters and prognosis; all B-cell NHL cases are negative, serving as a specific marker to distinguish T/NK cell NHL from B-cell NHL. | ||||